Table 1.
Baseline characteristics for nested case-control study participants, overall and stratified by TB recurrence outcome.
| Characteristic | All (n=24) | TB recurrence (n=12) | No TB recurrence (n=12) |
|---|---|---|---|
|
| |||
| Age in years at pre-ART; Mean (SD) | 34.7 (6.11) | 34.2 (5.73) | 35.2 (6.67) |
| Min to max | 24 – 47 | 24 – 43 | 24 – 47 |
|
| |||
| Female; n (%) | 16 (66.7%) | 8 (66.7%) | 8 (66.7%) |
|
| |||
| Integrated arm; n (%) | 16 (66.7%) | 8 (66.7%) | 8 (66.7%) |
|
| |||
| Previous history of TB; n (%) | 14 (58.3%) | 7 (58.3%) | 7 (58.3%) |
|
| |||
| Pre-ART CD4 count, cells/μl; Mean (SD) | 113 (72.06) | 114 (73.85) | 113 (73.50) |
| Min to max | 11 – 237 | 11 – 237 | 11 – 230 |
|
| |||
| Pre-ART Log viral load, copies/ml; Mean (SD) | 5.10 (0.83) | 5.14 (0.70) | 5.08 (1.00) |
| Min to max | 2.60 – 6.18 | 3.62 – 6.15 | 2.60 – 6.18 |
|
| |||
| Current time on ARVs in years*; Median (IQR) | 2.5 (1.9 – 3.6) | 3.1 (1.4 – 1.3) | 2.5 (0.7 – 1.6) |
|
| |||
| Current CD4 count, cells/μl; Mean (SD) | 453 (435.35) | 466 (604.73) | 439 (119.55) |
| Min to max | 14 – 2188 | 14 – 2188 | 271 – 671 |
|
| |||
| Current CD4 count, cells/μl; Median (IQR) | 354 (271 – 519) | 289 (105 – 470) | 423 (335 – 536) |
| Min to max | 14 – 2188 | 14 – 2188 | 271 – 671 |
|
| |||
| Current viral load suppressed**; n/N (%) | 19/23 (82.6%) | 8/12 (66.7%) | 11/11 (100%) |
|
| |||
| Weight, kg; Mean (SD) | 58.2 (8.75) | 59.1 (9.16) | 57.3 (8.62) |
|
| |||
| Body mass index; Mean (SD) | 21.6 (3.42) | 21.9 (3.62) | 21.4 (3.36) |
|
| |||
| Cavitory disease at occurrence; n (%) | |||
|
| |||
| No | 16 (66.7%) | 7 (58.3%) | 9 (75.0%) |
|
| |||
| One lung | 5 (20.8%) | 2 (16.7%) | 3 (25.0%) |
|
| |||
| Both lungs | 3 (12.5%) | 3 (25.0%) | 0 (0.0%) |
|
| |||
| Infiltrates at occurrence; n (%) | |||
|
| |||
| No | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|
| |||
| One lung | 7 (29.2%) | 1 (8.3%) | 6 (50.0%) |
|
| |||
| Both lungs | 17 (70.8%) | 11 (91.7%) | 6 (50.0%) |
|
| |||
| Adenopathy at occurrence; n (%) | |||
|
| |||
| No | 23 (95.8%) | 12 (100%) | 11 (91.7%) |
|
| |||
| One lung | 1 (4.2%) | 0 (0.0%) | 1 (8.3%) |
|
| |||
| Both lungs | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
|
| |||
| Pleural infusion at occurrence; n (%) | |||
|
| |||
| No | 21 (87.5%) | 12 (100%) | 9 (75.0%) |
|
| |||
| One lung | 3 (12.5%) | 0 (0.0%) | 3 (25.0%) |
|
| |||
| Both lungs | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
*
One TB recurrence case was not on ARVs at the time of enrolment on TRUTH and the pre-TB time point was a month prior to initiating treatment.
**
One patient, who did not experience TB recurrence, did not have VL data available at the first time point measured. Current refers to the very first time-point CD4 and VL were measured and duration of time on ARVs in this substudy.